China-made mRNA Covid vaccine targeting Omicron starts trial production, aims for 100 million doses in first phase | South China Morning Post

CanSino Biologics’ CS-2034 booster vaccine targets new Omicron variants driving a Covid-19 wave across China following the lifting of most pandemic curbs.